期刊文献+

四株临床分离百日咳鲍特菌主要抗原基因序列分析 被引量:3

Characteristics of the antigenic genes of four clinical Bordetella pertussis strains
原文传递
导出
摘要 目的 了解石家庄地区分离的百日咳鲍特菌4种抗原基因百日咳毒素S1亚单位(ptxS1)、外膜蛋白(Prn)、凝集素2(Fim2)和凝集素3(Fim3)的基因特征.方法 收集4株临床分离的百日咳鲍特菌,这4株菌于2002年分离自河北石家庄地区.分别对这4株菌的ptxS1、Prn、Fim2、Fim3主要抗原基因进行PCR扩增和测序,并与我国的百日咳鲍特菌疫苗生产株抗原基因序列以及GenBank中收录的百日咳基因序列进行比较、分析.结果 序列分析显示,新近分离的4株菌的S1基因亚型与我国疫苗生产菌株不同,均为A亚型,发现3种Prn基因亚型和3种Fim3基因亚型,核苷酸和氨基酸序列与我国疫苗生产菌株同源性均在99%以上.基因进化树显示与其他菌株的同源性也较高.结论 我国的临床分离菌株与疫苗生产菌株的主要抗原基因序列存在一定变异,为百日咳的流行病学研究和疫苗的研制积累理论依据. Objectives To analyze the characteristics of antigenic genes of clinical Bordetella pertussis strains recently isolated by analyzing the sequence of pertussis toxin S1 subunit(ptxS1) , pertactin (Prn) , fimbriae 2 (Fim2) and fimbriae 3 (Fim3 ) genes of four clinical isolates. Methods The 4 clinical isolates were collected in 2002 in Shijiazhuang of Hebei province. Four strains were isolated from pertussis patient's nasopharyngeal aspirate. ptxS1, Prn, Fim2 and Fim3 genes of these strains were amplified and sequenced. The sequences of those genes were compared with those of the isolates in GenBank and the isoaltes used in the production of pertussis vaccine in China. Results The results of the gene sequencing showed the four clinical isolates belonged to ptxS1 A type, which were different from those in vaccine strains. In addition, three Prn and three Fim'3 variants were observed in the four clinical isolates. Sequence analysis showed that the nucleotide sequence and deduced amino acid sequence of those strains had more than 99% identity with those in vaccine strains. The phylogenetic trees of those genes also showed these strains had a higher level of similarity with other Bordetella pertussis strains. Conclusion The four clinical isolates are different from vaccine strains in four antigenic genes, which laid a foundation for further studies on pertussis epidemiology,quality control and development of pertussis vaccine in China.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2010年第7期663-668,共6页 Chinese Journal of Laboratory Medicine
基金 科技部国家科技基础平台工作重点项目子课题医学微生物资源标准化整理、整合及共享试点项目(2005DKA21202-6)
关键词 博德特菌 百日咳 百白咳毒素 细菌外膜蛋白质类 毒力因子 鲍特菌属 抗原 细菌 菌毛蛋白质类 序列分析 Bordetella pertussis Pertussis toxin Bacterial outer membrane proteins Virulence factors,bordetella Antigens,bacterial Fimbriae proteins Sequence analysis
  • 相关文献

参考文献21

  • 1Poolman JT,Hallander HO.Acellular pertussis vaccine and the role of pertactin and fimbriae.Expert Rev Vaccines,2007,6:47-56.
  • 2Mooi FR,van Loo IHM,King AJ.Adaptation of Bordetella pertussis to vaccination:a cause for its reemergence.Emerg Infect Dis,2001,7:526-528.
  • 3中国药品生物制品检定所.生物制品检定标准操作细则.北京:中国药品生物制品检定所,1993.
  • 4Peppoloni S,Pizza M,De Magistris MT,et al.A cellular pertussis vaccine composed of genetically inactivated pertussis toxin.Physiol Chem Phys Med NMR,1995,27:355-361.
  • 5Poynten M,McIntyre PB,Mooi FR,et al.Temporal trends in circulating Bordetella pertussis strains in Australia.Epidemiol Infect,2004,132:185-193.
  • 6King AJ,Berbers C,van Oirschot HF,et al.Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity.Microbiology,2001,147:2885-2895.
  • 7van Loo IH,Heuvelman KJ,King AJ,et al.Multilocus sequence typing of Bordetella pertussis based on surface protein genes.J Clin Microbiol,2002,40:1994-2001.
  • 8Tsang RS,Lau AK,Sill ML,et al.Polymorphisms of the Fimbria 3 Gene of Bordetella pertussis Strains Isolated in Canada.J Clin Microbiol,2004,42:5364-5367.
  • 9Pertussis_Chinese[DB/OL] .Geneva,Switzerland:World Health Organization,2008[2010-04-26] .http://www.who.int/immunization/Pertussis_Chinese.pdf.
  • 10Galanis E,King AS,Varughese P,et al.Changing epidemiolngy and emerging risk groups for pertussis.CMAJ,2006,174:451-452.

二级参考文献35

  • 1陈正仁 何秋民.适应性百日咳菌种的获得与应用[J].微生物学报,1957,5(4):411-411.
  • 2Parton R. Review of the biology of bordetella pertussis. Biologic als,1999,27(2) :71-76.
  • 3World Health Organization. The world health report. Make a difference.Geneva, 1999.
  • 4Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognised:pertussis in UK infants. Arch Dis Child,2003,88:802-806.
  • 5Campins-Marti M, Cheng HK, Forsyth K, et al. Recommendations are needed for adolescent and adult pertussis immunization: rationale and strategies for consideration. Vaccine,2001,20:614-646.
  • 6World Health Organization. A global meeting. Pertussis surveillance.Geneva, 2001.
  • 7Frank-Michael C, Muller Jorg E. Hoppe CH. Wirsing von Konig, Laboratory diagnosis of pertussis: state of the art in 1997. J Clin Microbiol,1997,35 (10): 2435-2443.
  • 8Loeffelholz MJ,Thompson CJ,Long KS, et al. Comparison of PCR, culture, and direct fluorescent-antibody testing for detection of Bordetella pertussis. J Clin Microbiol, 1999,37(9):2872-2876.
  • 9Heininger U, Gabriela MD, Schlapfer S, et al. Clinical validation of a polymerase chain reaction assay for the diagnosis of pertussis by comparison with serology, culture and symptoms during a large pertussis vaccine efficacy trial. Pediatrics,2000,105 (3):e31.
  • 10Hallander HD. Microbiological and serological diagnosis pertussis. Clin Infect Dis, 1999,28(2): s99-106.

共引文献14

同被引文献8

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部